Express Pharma
Home  »  Pharma Ally  »  Phenomenex launches Lux Amylose-1 chiral stationary phase

Phenomenex launches Lux Amylose-1 chiral stationary phase

38

20150915ep51
Phenomenex has added Amylose-1 chiral stationary phase to its high-efficiency Lux polysaccharide chiral column line. The affordable Amylose-1 adds valuable enantioselectivity to the Lux column family with the chiral selector amylose tris (3,5-dimethylphenylcarbamate), and is a guaranteed alternative to other phases with the same chiral selector. Offered in 5µm particles, the new media is available in analytical columns and Phenomenex-patented Axia preparative column hardware, both of which are stable in normal phase, reversed phase, polar organic and SFC conditions. The Phenomenex Axia preparative format delivers longer column lifetime, higher efficiencies, improved performance and high reproducibility, compared with conventionally packedcolumns for lab-scale preparative HPLC and SFC chromatography.

The expanded Phenomenex Lux chiral column line of six amylose and cellulose chiral selectors comprises an affordable and complementary kit for chiral separations, featuring high efficiency, excellent loading capacity and pressure stability up to 300 bar in a wide range of conditions. Ideal applications for Lux columns include drug enantiomers from the pharma sector, chiral pesticide analysis in agrochemical settings, flavour analysis and production from the food industry, fragrance isolation and commercialisation in cosmetics and a range of other chiral-chemical raw materials such as intermediates and finished goods.

Phenomenex offers free chiral screening services with greater than 90 per cent success rates from its PhenoLogix application development group, along with over 2,000 chiral applications online that are easily searchable by compound structure or name.

Contact Details:
Jennifer Dahlgren,
Dahlgren Communications
Tel: (530) 263-6817
Email: [email protected]

Simon Lomas,
Phenomenex, Inc.
Tel: (310) 212-0555 (Extn. 2267)
Email: [email protected]

Comments are closed.